Abstract
The adult population of a large mental hospital was screened for tardive dyskinesia (TD). Approximately 11% of the hospital population showed signs of TD; females and the elderly were over-represented in the TD group. A representative sample of those with TD was selected and a control (non-TD) patient was chosen to match each of the TD subjects in age, sex, length of hospitalization, diagnosis, and race. The charts of these subjects were searched for any indices of brain damage and the complete psychotropic medication history was recorded. There was no difference between the TD and controls in the amount of psychotropics ingested, in the duration of administration, in the kinds of drugs, or in the organicity history. Women as a group, however, tended to have more polypharmacy than men. The role of neuroleptics in TD is discussed as well as other possible etiological factors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American College of Neuropsychopharmacology-Food and Drug Administration Task Force. Neurological syndromes associated with antipsychotic drug use. 289, 20–23
Asnis, G. M., Leopold, M. A., Duvoisin, R. C., Schwartz, A.: A survey of tardive dyskinesia in psychiatric outpatients. Paper presented at the 130th annual meeting of the American Psychiatric Association, Toronto, Canada (1977)
Ayd, F. J., Jr.: Neuroleptic-induced extrapyramidal reactions: incidence, manifestations and management. In: The future of pharmacotherapy new drug delivery system, F. J. Ayd, Jr., ed., pp. 77–88 Baltimore: International Drug Therapy Newsletter 1973
Crane, G. E.: High doses of trifluoperazine and tardive dyskinesia. Arch. Neurol. 22, 176–180 (1970)
Crane, G. E.: Persistent dyskinesia. Br. J. Psychiatry 122, 395–403 (1973)
Crane, G. E., Smeets, R. A.: Tardive dyskinesia and drug therapy in geriatric patients. Arch. Gen. Psychiatry 30, 341–343 (1974)
Degkwitz, R., Wenzel, W.: Persistent extrapyramidal side effects after long-term application of neuroleptics. In: Neuropsychopharmacology, International Congress Series No. 129, H. Brill, ed. Amsterdam: Excerpta Medica 1967
Edwards, H.: The significance of brain damage in persistent oral dyskinesia. Br. J. Psychiatry 116, 271–275 (1970)
Ericksen, S., Haraszti, J., Dekirmenjiar, H., Chang, S., Casper, R., Davis, J.: Haloperidol dose, plasma level and response. Paper presented at NCDEU meeting, Key Biscayne, Florida (1977)
Fann, W. D., Davis, J. M., Janowski, D. S.: The prevalence of tardive dyskinesia in mental hospital patients. Dis. Nerv. Syst. 37, 182–186 (1972)
Faurbye, A., Rasch, P. J., Peterson, P. B., Brandborg, G., Pakkenberg, H.: Neurological symptoms in pharmacotherapie of psychose. Acta Psychiatr. Scand. 40, 10–27 (1964)
Gardos, G., Cole, J., La Brie, R. A.: Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis. Neuropsychopharmacology 1, 147–154 (1977)
Granacher, R. P., Baldessarini, R. J., Cole, J. O.: Deanol for tardive dyskinesia [cont.] [Letter]. New Engl. J. Med. 292, 926–927 (1975)
Hunter, R., Earl, C. J., Thoenicroft, S.: An apparently irreversible syndrome of abnormal movements following phenothiozine medication. Proc. R. Soc. Med. 57, 24–28 (1964)
Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P., Villeneuve, R.: Epidemiology of tardive dyskinesia. Dis. Nerv. Syst. 37, 210–214 (1976)
Kane, J., Wegner, J., Strune, F., Quitkin, F., Rifkin, A., Kline, D. F.: The mitten pattern as a potential EEG predictor of tardive dyskinesia. Paper presented at the NCDEU meeting, Key Biscayne, Florida (1977)
Kennedy, P. F., Hershon, H. I., McGuire, R. J.: Extrapyramidal disorders after prolonged phenothiazine therapy. Br. J. Psychiatry 118, 509–518 (1971)
Kiloh, L. G., Smith, S. J., Williams, S. E.: Antiparkinson drugs as causal agents in tardive dyskinesia. Med. J. Aust. 2, 591–593 (1973)
Ogita, K., Yagi, G., Itoh, H.: Comparative analysis of persistent dyskinesia of long-term usage with neurolepties in France and in Japan. Folia Psychiatr. Neurol. Jpn. 29, 315–320 (1975)
Polizos, P., Engelhardt, D. M., Hoffman, S. P.: CNS consequences of psychotropic drug withdrawal in schizophrenic children. Psychopharmacol. Bull. 9, 34–35 (1973)
Pryce, I. G., Edwards, H.: Persistent oral dyskinesia in female mental hospital patients. Br. J. Psychiatry 112, 983–987 (1966)
Simpson, G. M., Amin, M., Kunz-Bartholini, E., Watts, T. P. S., Laska, E.: Problems in the evaluation of the optimal dose of a phenothiazine (butaperazine). Dis. Ner. Syst. 29, 478–484 (1968)
Tarsy, D., Baldessarini, R. J.: The tardive dyskinesia syndrome. In: Clinical neuropharmacology, H. L. Klawans, ed. New York: Raven 1976
Turek, I., Kurland, A. A., Hanlon, T. E., Bohm, M.: Tardive dyskinesia: Its relation to neuroleptic and antiparkinson drugs. Br. J. Psychiatry 121, 605–612 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simpson, G.M., Varga, E., Lee, J.H. et al. Tardive dyskinesia and psychotropic drug history. Psychopharmacology 58, 117–124 (1978). https://doi.org/10.1007/BF00426893
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00426893